Majority Of Wyeth Growth Pegged To Licensed Biotech Products, Execs Say
This article was originally published in The Pink Sheet Daily
Executive Summary
Half of big pharma’s developmental pipeline should come from outside innovators, Wyeth BioPharma’s Redmund says.
You may also be interested in...
Repercussions Of A Merger: TRU-015 Potentially Up For Grabs
Change-of-control provision may return Phase IIb rheumatoid arthritis program to biotech developer. Would Pfizer pay (again) to be the partner?
Repercussions Of A Merger: TRU-015 Potentially Up For Grabs
Change-of-control provision may return Phase IIb rheumatoid arthritis program to biotech developer. Would Pfizer pay (again) to be the partner?
Wyeth Pulls Plug On Trubion Candidate In NHL
Firms forge ahead with rheumatoid arthritis program.